OLYMPIA-3 trial at ASCO 2026 shows odronextamab plus CHOP in higher-risk B-cell lymphoma delivers strong MRD-negative CRs with fewer visits.
Matthew Matasar, MD
Advertisement
Matthew Matasar, MD, is the chief of blood disorders at Rutgers Cancer Institute.
Articles by Matthew Matasar, MD
At the 30th European Hematology Association (EHA) Congress, hematology experts highlight breakthroughs in treatment, the importance of patient voices, and challenges in making innovations accessible worldwide.
Adding polatuzumab vedotin to rituximab, gemcitabine, and oxaliplatin (R-GemOx) significantly improved overall survival in transplant-ineligible patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL), according to Matthew Matasar, MD, of Rutgers Cancer institute.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Legend Biotech’s CAR T-cell Therapy Shows Early Promise in SCLC, Other Tumors
2
Flatiron’s AI-Driven Telescope Makes Data Access More User-Friendly
3
Social Factors May Match, Outpace Genetic Risk in Disease Prediction
4
Long-Term, Consistent Resistance Training Linked to Substantially Lower Type 2 Diabetes Risk
5